• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
in-search-of-the-differences-that-make-the-difference
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Discovery

In search of the differences that make the difference

Ambitious scientist accelerates research into African genomic diversity and health challenges with internship

By
Paul Johnson
Aug 25, 2016

Born to parents who had fled war-torn Angola for the relative safety of the Democratic Republic of Congo, Mamana Mbiyavanga is now pursuing cutting-edge genomic questions at an ultramodern research lab in Switzerland. 

A doctoral student at the University of Cape Town (UCT) in South Africa, Mbiyavanga is in the middle of a Next Generation Scientist internship at the Novartis Institutes for BioMedical Research (NIBR) in Basel, Switzerland. Mbiyavanga is using his three-month stint at NIBR to conduct genetic analysis of DNA samples from two major African populations. His aim is to contribute to the understanding of genomic diversity of African populations and the discovery and development of more effective drugs and diagnostics.

“Until now, most studies of genomic variation have been performed in European populations. There’s much less data for African populations, even though there is far greater diversity in these groups,” explains Mbiyavanga. “Investigating diversity among subpopulations in Africa will help in mapping the genetic causes of disease – for African people and, by implication, humanity as a whole.”

As part of his project, Mbiyavanga is also drilling into pharmacogenomics. “Genomic differences play a big part in how people respond to drugs,” he says. “Understanding the impact of these differences will help in developing medicines and dosing regimes that are safe and effective for African people.”

Investigating diversity among subpopulations in Africa will help in mapping the genetic causes of disease – for African people and, by implication, humanity as a whole.

Mamana Mbiyavanga, doctoral student and Next Generation Scientist intern at Novartis

Mbiyavanga’s work at NIBR is the latest phase in a story that began when his parents left Angola at the height of the country’s long and bloody civil war. They settled in the neighboring DR Congo, where Mbiyavanga was born. Early on, and encouraged by family and teachers, his first ambition was to become a medical doctor, but a talent for numbers took him on a different path that led to a degree in computer science and mathematics. During post-grad studies at the African Institute of Mathematical Sciences in South Africa, Mbiyavanga was introduced to bioinformatics – the study of biological data using computer science, statistics and mathematics. “My boyhood wish to go into medicine had never gone away,” he says. “Bioinformatics gave me a chance to understand disease and help develop therapies by applying my interest and training in mathematics and computer science.” He moved on to UCT for a master’s degree in bioinformatics and then enrolled in his current PhD program. 

Following the science at NIBR

Mbiyavanga saw an internship at NIBR as a way to accelerate his PhD research by getting hands on experience using next-generation sequencing technology. This technology has revolutionized genomic research by enabling an entire human genome to be sequenced in a single day. 

“I knew the technology would be right at the cutting edge,” says Mbiyavanga. “It’s way ahead of what’s available in most academic labs.”

Mbiyavanga’s day-to-day interactions with his colleagues have been equally rewarding. “People have been so ready to answer questions and share their knowledge,” he says. “And the emphasis everyone puts on innovation – on accepting risk and embracing failure – has been enriching. It’s given me a new perspective on the scientific endeavor.”

On a practical level, Mbiyavanga says he will return to Africa with newly acquired scientific skills. “The team here has a great depth of expertise in analysis of sequencing results. What I’m learning will be a real asset to my lab back at UCT.”

Over the longer term, Mbiyavanga wants to continue building genomics capability in Africa in order to improve how disease is diagnosed and treated on the continent. “I’m a firm believer in African scientists working on African problems,” he says. “Who knows – one day I might even play a part in building an African pharmaceutical industry.”

The mentor’s perspective

Martin Beibel, a bioinformatics specialist on NIBR’s molecular profiling team, has been Mbiyavanga’s mentor during his internship. “Normally, we examine single genes or genetic pathways to inform the search for new drug targets or elucidate the molecular mechanism of drug action and response. It has been thought-provoking to work with Mamana and apply our technology to African populations that have not been adequately studied so far.”

Guglielmo Roma, Head of Molecular Profiling in the Developmental and Molecular Pathways group at NIBR, adds: “Having Mamana on the team has given us all new insights into healthcare challenges in Africa and opened our eyes to the progress and potential of the work being done on genomic diversity. 

“We plan to stay in touch with him over the years – as we have done with other interns we’ve worked with. This helps us expand our network of potential future scientific collaborators.”

Supporting the next generation

The Next Generation Scientist initiative gives young researchers and academics from emerging economies exposure to pharmaceutical research and development through internships at Novartis. Since 2011, more than 120 scientists from 24 countries in Africa, Asia and Latin America have taken part.

Main image: Mbiyavanga is using his three-month stint at NIBR to conduct genetic analysis of DNA samples from two major African populations. Photo by Gabriel McClelland

Shareline

Ambitious scientist accelerates research into African genomic diversity and health challenges with internship
Tweet Tweetpopo
Tags: 
Next Generation Scientist, Novartis Institutes for BioMedical Research

Paul Johnson

Paul Johnson

is a freelance corporate writer. He has a long-standing interest in health and medicine, especially game-changing discoveries and the people who make them. Paul is also a part-time counsellor and novice gardener.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

RNA strand
Discovery

Take a visual tour of medicines that target RNA

A kidney patient is smiling at the camera
Discovery

New hope for treating inflammatory diseases of the kidney

2D rendering of kidneys
Discovery

Predictive analytics could bring medicines to patients faster

You are here

  1. Home ›
  2. Stories ›
  3. Discovery

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.